Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484891 | 0.94 | OPRL1 (0.53) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL16579984 | 0.93 | KMT2A (0.65) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL4691043 | 0.91 | CYP3A4 (0.55) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL6999779 | 0.86 | POLB (0.55) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL18123311 | 0.86 | POLB (0.65) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL2695038 | 0.85 | OPRL1 (0.61) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| Hydrochloric Acid SCHEMBL7393308 | 0.83 | CYP3A4 (0.57) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL5995214 | 0.81 | POLB (0.77) | OPRL1POLBMEN1KMT2AGAA | |
| SCHEMBL18826008 | 0.81 | KMT2A (0.62) | OPRL1CYP3A4HSD17B10POLBMEN1 | |
| SCHEMBL6079469 | 0.80 | POLB (0.59) | OPRL1CYP3A4HSD17B10POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118234707-A | Cyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023001069-A1 | MACROCYCLIC AMIDE COMPOUNDS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-5597818-A | CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5595990-A | TREATMENT OF CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0730454-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0730453-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995032635-A1 | CHEWING GUM HAVING IMPROVED PROPERTIES AND CONTAINING MEDIUM CHAIN TRIGLYCERIDES | WM. WRIGLEY JR. COMPANY (US) | 1995-12-07 | — | — | WO | disclosed |
| US-5428031-A | Benzodiazepine analogs; cardiovascular disorders | MERCK & CO., INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5426185-A | Antiarrhythmia agents having reduced side effects | MERCK & CO., INC. (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995014471-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014470-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0587134-A2 | Cyclic urea derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | OPRL1 138/4885CYP3A4 3781/4885HSD17B10 4072/4885 |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | OPRL1 4319/4885CYP3A4 4863/4885HSD17B10 2604/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | OPRL1 4319/4885CYP3A4 4863/4885HSD17B10 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.